Oct 23 (Reuters) - Australian Clinical Labs Ltd (ACL) :
- NEGLIGIBLE COVID REVENUE IS EXPECTED IN FY24 RESULT
- Q1 VOLUME RESULTS IN UNDERLYING CORE BUSINESS SHOW VOLUME GROWTH OF 5% OVER PCP
- WORKFORCE AVAILABILITY AND ACCESS TO SERVICES AFFECTING HEALTHCARE SERVICE VOLUMES
- WILL ACHIEVE A SIMILAR EBIT RESULT IN FY24 OF BETWEEN A$65 MILLION AND A$70 MILLION
News: ACL Australian Clinical Labs Says Negligible COVID Revenue Expected In FY24 Result
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.60 |
Change
-0.030(1.14%) |
Mkt cap ! $510.6M | |||
| Open | High | Low | Value | Volume |
| $2.64 | $2.65 | $2.59 | $901.1K | 345.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18300 | $2.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| ACL (ASX) Chart |